Patent ID: 6790839
Filing Date: 2004-09-14
Classification: A61K

Abstract:
A method for inducing G-CSF secretion within the body of a subject, comprising administering to the subject an effective amount of an agent that is an agonist of the adenosine A1 receptor for inducing said G-CSF secretion, wherein said agonist of the adenosine A1 receptor is a compound of general formula (I): wherein R1 represents a lower alkyl, substituted or unsubstituted cycloalkyl; a hydroxyl or hydroxyalkyl; a phenyl or lower alkylphenyl, the phenyl or lower alkylphenyl optionally substituted by one or more substituents; â€”SORc, â€”SO2Rc, â€”SO3H, â€”SO2NRaRb, â€”ORa, â€”SRa, â€”NHSO2Rc, â€”NHCORa, â€”NRaRb, or â€”NHRaCO2Rb; wherein Ra and Rb represent independently a hydrogen, lower alkyl, alkanoyl, amino, phenyl or naphthyl, the alkyl group optionally being substituted with a substituted or unsubstituted phenyl or phenoxy group; or when R1 represents â€”NRaRb, said Ra and Rb form together with the nitrogen atom a 5- or 6-membered heterocyclic ring optionally containing a second heteroatom selected from the group consisting of oxygen and nitrogen, which second nitrogen heteroatom may optionally be substituted by hydrogen or lower alkyl; or â€”NRaRb is a group of general formulae (II) or (III): â€ƒwherein n is an integer from 1 to 4; Z is hydrogen, lower alkyl or hydroxyl; Y is hydrogen, lower alkyl, or ORâ€² where Râ€² is hydrogen, lower alkyl or lower alkanoyl; A is a bond or a lower alkylene; X and Xâ€² are each independently hydrogen, lower alkyl, lower alkoxy, hydroxy, lower alkanoyl, nitro, haloalkyl, halogen, amino, mono- or di-lower alkyl amino, or when X and Xâ€² are taken together a methylenedioxy group; Rc represents a lower alkyl; or R1 represents an epoxide substituent of general formulae (IVa) or (IVb): â€ƒwherein M is a lower alkylenyl group; R2 represents hydrogen; halogen; substituted or unsubstituted lower alkyl or alkenyl group; lower haloalkyl or alkenyl; cyano; acetoamido; lower alkoxy; lower alkylamino; NRdRe where Rd and Re are independently hydrogen, lower alkyl, phenyl or phenyl substituted by lower alkyl, lower alkoxyl, halogen or haloalkyl; â€”SRf where Rf is hydrogen, lower alkyl, lower alkanoyl, benzoyl or phenyl; W represents â€”OCH2â€”, â€”NHCH2â€”, â€”SCH2â€” or â€”NH(C&boxH;O)â€”; R3, R4 and R5 represent independently a hydrogen, lower alkyl or lower alkenyl, branched or unbranched C1-C12 alkanoyl, benzoyl or benzoyl substituted by lower alkyl, lower alkoxy or halo group; or R4 and R5 form together a 5-membered ring optionally substituted by a lower alkyl or alkenyl; or R3 further represents independently a phosphate, hydrogenphosphate or dihydrogen phosphate, or an alkali metal or ammonium or dialkali or diammonium salt thereof; R6 represents a hydrogen or halogen atom; or one of the substituents R1 to R6 is a sulfohydrocarbon radical of the formula Rgâ€”SO3â€”Rhâ€”, wherein Rg is selected from the group consisting of C1-C10 alkylenyl, phenylenyl and substituted lower alkyl phenylenyl group and Rh represents a monovalent cation; wherein when R1 is a substituent of general formula (IVb), the N1 of the compound of general formula (1) may optionally bear an oxygen atom; and pharmaceutically acceptable salts or solvates of said compound.